Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
...gnosis...
...lorectal carcinoma patients being c...
...600 (BRAF c. 1799 (p.V600) mutational analysi...
...mutational analysis should be perf...
Clinicians should order mismatch repair status t...
...is insufficient evidence to recommend...
...sufficient evidence to recommend PIK3CA m...
...e is insufficient evidence to recom...
...tatic or recurrent colorectal carcinoma tissue...
...n fixed paraffin embedded tissue is an...
...must use validated colorectal carcinoma molecula...
...ce of molecular biomarker testing f...
...aboratories must validate the performance of...
...tories must provide clinically app...
...ar and IHC biomarker testing in colorectal car...
...ories should establish policies to en...
...bers of the patient’s medical team...
...at require send out of tests for treatment pre...
...t evaluate candidate specimens for biomarker te...
...ies should use colorectal carcinoma molecular bi...
...rectal carcinoma molecular biomarker res...
...rcinoma molecular biomarker testing reports...
...tories must incorporate colorectal carcin...
...Outcomes of RAS Mutations and Ant...
...2. Concordance Rates Between Primary and Meta...